Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: subcision with PDRN vs HA injection.
- Who it may be relevant to
- Registry conditions: Atrophic Acne Scars. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Subcision With Injection of Poly Deoxyribonucleotide Versus Subcision With Injection of Non-cross Linked Hyaluronic Acid in Rolling Acne Scars Treatment : A Split Face Randomized Controlled Clinical Trial.
Overview
The aim of this study is to evaluate and compare the efficacy and safety of two different injectable agents combined with subcision for treating rolling acne scars. In this split-face clinical trial, each participant will receive subcision on both sides of the face. One side will then be treated with an injection of Polydeoxyribonucleotide (PDRN), while the other side will receive an injection of non-cross linked Hyaluronic acid (HA). The clinical outcomes and improvement in scar appearance will be assessed and compared between both treatments
Interventions
- Procedure subcision with PDRN vs HA injection
Each participant will receive two different treatments on each side of the face. One side will be treated with subcision followed by PDRN injection, while the other side will be treated with subcision followed by non-cross linked Hyaluronic Acid injection. Clinical assessment and 3D image analysis will be used for evaluation.
Primary outcome measures
- Percent change in atrophic acne scar topography [Time frame: Baseline, Week 12, and Week 24 (3 months after last injection).]
- Change in Goodman and Baron Quantitative Score. [Time frame: Baseline, Week 12, and Week 24 (3 months after last injection).]
Secondary outcome measures (9)
- Patient and Observer Scar Assessment Scale (POSAS) - Observer Scale [Time frame: Baseline, Week 12, and Week 24 (3 months after last injection).]
- Patient and Observer Scar Assessment Scale (POSAS) - Patient Scale [Time frame: Baseline, Week 12, and Week 24 (3 months after last injection)]
- Proportion of patients with clinically significant POSAS improvement [Time frame: Week 12 and Week 24]
- Proportion of patients with \ge30% improvement in Goodman and Baron score [Time frame: Week 12 and Week 24.]
- Change in total atrophic acne scar counts [Time frame: Baseline, Week 12, and Week 24.]
- Success rate based on Scar Global Assessment (SGA) [Time frame: Week 12 and Week 24.]
- Patient Satisfaction Score [Time frame: Week 12 and Week 24.]
- Absolute values of scar topography [Time frame: Baseline, Week 12, and Week 24.]
- Absolute values of Goodman and Baron Quantitative Score [Time frame: Baseline, Week 12, and Week 24]
Eligibility criteria
Inclusion criteria
- Moderate to severe mainly rolling acne scars per validated scale (Goodman \& Baron Grade 3-4)
- Scars must be bilaterally distributed, allowing for split-face comparison
- Stable acne (no active nodulocystic lesions, pustules, or recent outbreaks for ≥6 months)
- No scar treatments (e.g., fillers, laser, microneedling) within the past 12 months
- All skin types.
- Both genders above 18 years old
Exclusion criteria
- Systemic retinoid treatment within the last 6 months
- Active inflammatory acne
- Lidocaine sensitivity
- Pregnancy and lactation
- Severe systemic illness or malignancy
- Use of anticoagulant or antiplatelet medications (unless cleared) Use of oral isotretinoin within the past 6 month
- Herpes libialis, bacterial infection, other infections such as HBV, HCV or HIV
- Tendency to keloid formation
- Allergy to fish and salmon
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Cairo University, Dermatology Department — Cairo
Identifiers
NCT: NCT07547956 · MS-376-2025